Emergence of biomarkers in nephropharmacology.
Blood-urea nitrogen, serum creatinine and urine output have long been used as markers of kidney function despite their known limitations. In the past few years, a number of novel biomarkers have been identified in the urine and blood that can detect kidney injury early. Although, to date, none of these biomarkers are in clinical use, many have been validated as reliable and sensitive, allowing detection of kidney injury before serum creatinine levels rise and urine output drops. These markers have been evaluated in great detail in animal models and to a lesser extent in humans in postcardiopulmonary bypass and sepsis. There is relatively scarse data on the use of these biomarkers in the detection of kidney injury associated with the use of pharmacologic agents. The purpose of this article is to summarize these data and highlight the potential utility of these biomarkers in nephropharmacology.
Tulane University Medical School, Department of Medicine, Nephrology Section 1430 Tulane Avenue, New Orleans, LA, USA.
Enver
E
Khan
Vecihi
V
Batuman
Juan J L
JJ
Lertora
D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis* / Q000652:urine; D000818:Animals; D054316:Biomarkers, Pharmacological / Q000097:blood* / Q000652:urine*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D006801:Humans; D007668:Kidney / Q000187:drug effects
D054316:Biomarkers, Pharmacological